IP Library Granted Patent US 10,596,358
Granted Patent B2
US 10,596,358 · App. 15/658,172 · Granted Mar 24, 2020

Devices and methods for intraluminal retention and drug delivery

Inventors: David Mathew Johnson (San Francisco, CA); Martin Sheridan (Redwood City, CA); Scott A. Uhland (San Jose, CA); Ramkumar Abhishek (Mountain View, CA); Eric Peeters (Mountain View, CA); Timothy J. Curley (San Carlos, CA); Felicia Linn (San Jose, CA); Philipp H. Schmaelzle (Los Altos, CA)
Assignee: PALO ALTO RESEARCH CENTER INCORPORATED
A61M31/002A61D7/00A61M5/1452A61M2210/1433A61M2210/1475
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,596,358
App. No.
15/658,172
Granted
Mar 24, 2020
Kind
B2
Abstract

Retention devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and at least one reservoir contained within the housing. The at least one reservoir may have an actuation end and a release end and contain at least one drug formulation. A plug may be contained within the at least one reservoir and be moveable from the actuation end toward the release end. The device may also include an actuation system operably connected to the actuation end of the at least one reservoir and configured to drive the at least one drug formulation from the reservoir. The device may also include at least one retention member affixed to the housing and movable between a non-stressed position, a deployment position, and a retention position for retaining the device in an intraluminal location in the subject.

Claims (51)

1. A device for drug delivery comprising:

a housing configured for intraluminal deployment into a lumen of a human or animal subject;

at least one reservoir contained within the housing, the at least one reservoir having an actuation end and a release end and containing at least one drug formulation;

a plug within the at least one reservoir and moveable from the actuation end toward the release end;

an actuation system operably connected to the actuation end of the at least one reservoir and configured to drive the at least one drug formulation from the reservoir;

at least one retention member affixed to the housing and movable between a non-stressed position, a deployment position, and a retention position for retaining the device in an intraluminal location in the subject; and

a retention member release mechanism configured to be slideable with respect to the housing in a direction from the release end toward the actuation end to transform the retention member from the retention position to the deployment position.

2. The device of claim 1 , wherein the at least one retention member is in substantially the same position in the deployment position and in the retention position.

3. The device of claim 1 , wherein the at least one retention member comprises at least two flexible arms that are substantially perpendicular to the housing in the non-stressed position and substantially parallel to the housing in the deployment position.

4. The device of claim 3 , wherein in the retention position, the at least two flexible arms are in a position between the non-stressed position and the deployment position.

5. The device of claim 3 , wherein the at least two flexible arms are configured to be deformed from the non-stressed position to the deployment position upon intraluminal deployment.

6. The device of claim 5 , wherein the at least two flexible arms are configured to be deformed from the deployment position to the retention position after intraluminal deployment.

7. The device of claim 5 , wherein the at least two flexible arms are configured to be elastically deformed.

8. The device of claim 1 , wherein the at least one retention member comprises at least one arm having a first end and a second end, the first end being affixed to the housing, and the second end being distal the housing in the non-stressed position and proximal the housing in the deployment position.

9. The device of claim 8 , wherein in the retention position, the second end of the at least one arm is in a position between the non-stressed position and the deployment position.

10. The device of claim 8 , wherein the at least one arm comprises a porous membrane in fluid communication with the release end of the at least one reservoir, the porous membrane being configured to distribute the at least one drug formulation driven from the at least one reservoir to a tissue area adjacent the at least one arm when the device is deployed in the human or animal subject.

11. The device of claim 8 , wherein the at least one arm is a flexible arcuate arm configured to be deformed from the non-stressed position to the deployment position upon intraluminal deployment.

12. The device of claim 11 , wherein the at least one arm is configured to be deformed from the deployment position to the retention position after intraluminal deployment.

13. The device of claim 8 , further comprising at least one removal cord connected to the at least one arm and configured to move the second end of the at least one arm toward the housing upon pulling the at least one removal cord.

14. The device of claim 8 , wherein the release mechanism comprises a sleeve positioned about the housing and configured to be slideable about the at least one arm such that the at least one arm assumes a retracted position adjacent the housing when the sleeve is slid from the first end of the at least one arm toward the second end of the at least one arm.

15. The device of claim 14 , further comprising at least one removal cord connected to the sleeve and configured to slide the sleeve about the at least one arm and move the at least one arm from the retention position to the retracted position to facilitate insertion and removal of the device.

16. The device of claim 1 , wherein the at least one retention member comprises:

two flexible arms that are substantially perpendicular to the housing in the non-stressed position and substantially parallel to the housing in the deployment position;

and a third arm at an opposing end of the housing from the two flexible arms, the third arm being configured to exert a force on a portion of the lumen such that a portion of the housing contacts a wall of the lumen in the retention position.

17. The device of claim 1 , wherein the housing is pliant at one or more points such that in the non-stressed position the housing is not straightened, and in the deployment position the housing is straightened.

18. The device of claim 1 , wherein the housing is configured for intravaginal or intrauterine deployment and the actuation system is configured to drive the plug and displace the at least one drug formulation.

19. A device for drug delivery comprising:

a tubular housing configured for intraluminal deployment into a human or animal subject;

at least one reservoir contained within the housing, the at least one reservoir having an actuation end and a release end and containing at least one drug formulation;

a plug within the at least one reservoir and moveable from the actuation end toward the release end;

an actuation system operably configured to drive the plug and displace the at least one drug formulation from the reservoir; and

a retention sleeve that comprises at least two arms, each arm having a first end and a second end, the first ends being affixed to the housing and the second ends being affixed to a ring positioned about the housing and slideable between a deployment position in which the at least two arms are adjacent the housing and a retention position in which the at least two arms are outwardly expanded.

20. A method of drug delivery comprising:

providing a drug delivery device that comprises:

a housing,

at least one retention member affixed to the housing,

at least one reservoir within the housing, the at least one reservoir having a release end and an actuation end and containing at least one drug formulation, and

a plug within the at least one reservoir and moveable from the actuation end toward the release end;

transforming the retention member from a non-stressed position into a deployment position;

deploying the device into a mucosal lumen of a human or animal subject;

transforming the retention member from the deployment position into a retention position;

actuating an actuation system to drive the plug and displace the at least one drug formulation out of the at least one reservoir while the device is retained in the mucosal lumen; and

transforming the retention member from the retention position to the deployment position by moving a release mechanism along the housing in a direction from the release end toward the actuation end.

21. A method of drug delivery comprising:

providing a drug delivery device that comprises:

a tubular housing,

a retention sleeve having at least two arms, each arm having a first end and a second end, the first ends being affixed to the housing and the second ends being affixed to a ring positioned about the housing,

at least one reservoir within the housing;

inserting the device into a mucosal lumen of a human or animal subject;

sliding the ring to outwardly expand the at least two arms of the retention sleeve into a retention position; and

actuating an actuation system to drive the at least one drug formulation out of the at least one reservoir.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2025
From: XEROX CORPORATION
To: GENESEE VALLEY INNOVATIONS, LLC
Reel/Frame 073842/0479 →
SECOND LIEN NOTES PATENT SECURITY AGREEMENT Recorded Jul 2, 2025
From: XEROX CORPORATION
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 071785/0550 →
FIRST LIEN NOTES PATENT SECURITY AGREEMENT Recorded Apr 11, 2025
From: XEROX CORPORATION
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 070824/0001 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT RF 064760/0389 Recorded Feb 13, 2024
From: CITIBANK, N.A., AS COLLATERAL AGENT
To: XEROX CORPORATION
Reel/Frame 068261/0001 →
SECURITY INTEREST Recorded Feb 13, 2024
From: XEROX CORPORATION
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 066741/0001 →
SECURITY INTEREST Recorded Nov 20, 2023
From: XEROX CORPORATION
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 065628/0019 →
CORRECTIVE ASSIGNMENT TO CORRECT THE REMOVAL OF US PATENTS 9356603, 10026651, 10626048 AND INCLUSION OF US PATENT 7167871 PREVIOUSLY RECORDED ON REEL 064038 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2023
From: PALO ALTO RESEARCH CENTER INCORPORATED
To: XEROX CORPORATION
Reel/Frame 064161/0001 →
SECURITY INTEREST Recorded Jun 22, 2023
From: XEROX CORPORATION
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 064760/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2023
From: PALO ALTO RESEARCH CENTER INCORPORATED
To: XEROX CORPORATION
Reel/Frame 064038/0001 →
Continuity (2)
Division 13742203 · Jan 15, 2013
Related Publication 20170319834A1 · Nov 9, 2017